Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 4,118 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Knee Injuries, Knee Osteoarthritis
Interventions: Cutaneous Stimulation, Knee Sleeve; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Infertility, Female, Obesity
Interventions: Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone; Other · Dietary Supplement · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Subjects, Pharmacokinetics of YM178
Interventions: YM178 OCAS, Ketoconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more

Conditions: Sleep, Nightshift Work
Interventions: Single-Sensor Tracking (In-Lab), Multi-Sensor Sleep Tracking (In-Lab), Multi-Sensor Sleep Tracking (At-Home); Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Cetirizine, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Interventions: 64Cu-LNTH-1363S; Combination Product
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 15 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Stanford, California + 2 more

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dravet Syndrome
Interventions: Transcranial Magnetic Stimulation (TMS), Electroencephalogram (EEG); Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 30 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Diaper Dermatitis, Urinary Tract Infections, Infection, Depressive Symptoms, Stress
Interventions: Diaper Incentive, Conditional Cash Transfer Condition; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Posttraumatic Stress Disorder
Interventions: Psilocybin, MDMA; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure
Interventions: Thyroid hormone T3, Control Group; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Sleep Deprivation, Sleep
Interventions: 2-lead limited electroencephalography recording; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Music Education
Interventions: Music Training - Choir participation; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 50 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression
Interventions: Psychoeducation, Testimonials and Saying is believing exercises, Action planning, Breathing exercise; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 887 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cocaine Dependence
Interventions: Clavulanic Acid Only Product, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Interventions: RGX-314; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Early-phase Safety and PK Study of a Vaginal Gel
Interventions: YASO GEL, Placebo gel; Drug
Lead sponsor: Yaso Therapeutics Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Interventions: Oral glucose tolerance test (OGTT), Skin punch biopsy; Diagnostic Test · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma
Interventions: CCW702; Drug
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: San Diego, California • Baltimore, Maryland • Detroit, Michigan + 2 more

Conditions: Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions: DKK1; Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Living Organ Donation
Interventions: Organ Donation Workshop, End of Life Care Workshop; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function; Drug · Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Gait Modification Treatments for Knee Pathology

Mediators of Abnormal Reproductive Function in Obesity (MARO)

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

The Use of Multiple Sensors to Track Sleep in Nightshift Workers

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Intervention to Reduce Diaper Need and Increase Use of Pediatric Preventive Care

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

Validation of Frontal EEG to Formal Polysomnography in the ICU

Short-Term Music Training and Auditory Processing in Older Adults

Active Elements of Digital Single-session Interventions

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

FIH Lead-in Study of YASO GEL Followed by a Phase 1 Randomized, Double-blind Study to Assess Safety and Pharmacokinetics of YASO GEL

Role of Insulin Action in Psoriasis Pathogenesis

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Informing American Muslims About Living Donation

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.